Marta Jimenez

9PUBLICATIONS
64CO-AUTHORS
Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.

Abderaouf Hamza, Pierre Gestraud, Maryam Karimi

|Jun 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.

Edith Borcoman, Bastien Cabarrou, Miguel Francisco

|Jun 12, 2025
Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature.

Solenn Barraud, Sophie Vacher, Camille Schiffler

|Aug 01, 2024
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors.

Marie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas

|Jan 05, 2024
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.

Hélène Vanacker, Isabelle Treilleux, Camille Schiffler

|Jul 24, 2023
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.

Fernanda Mosele, Elise Deluche, Amelie Lusque

Pageof 2

Frequent Collaborators

7 joint publications

Fabrice Andre

4 joint publications

Christophe Le Tourneau

4 joint publications

Thomas Bachelot

3 joint publications

Pierre Gestraud